

# ASX ANNOUNCEMENT

12 April 2023

## Anteris Technologies Receives Utility Patent for Novel Transcatheter Heart Valve Replacement Technology

**BRISBANE, Australia** and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) is pleased to announce that the United States Patent and Trademark Office has issued a utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).

DurAVR™ THV is a first-in-class biomimetic valve uniquely designed to mimic the performance of a healthy human heart valve. The patent number 11,622,853, which expires 30 September 2042, further confirms that the Company has developed a differentiated heart valve technology through its innovative single-piece, shaped-tissue design. The Company believes the unique aspects of the DurAVR™ design, including the single-piece valve construction, account for the excellent clinical results to date.

“The patent signifies the extraordinary work by our team of engineers around the world responsible for the design of DurAVR™ THV. The granting of this patent enhances the broad IP protection of DurAVR™, strengthening our competitive position in the TAVR field,” said Wayne Paterson, CEO.

### ENDS

#### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

#### Authorisation and Additional information

This announcement was authorised by the Board of Directors.

#### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



For personal use only

**For more information:**

**Investor contact**

Deanne Curry

GRACosway

E: [investors@anteristech.com](mailto:investors@anteristech.com)

M: +61 414 388 997

**Media contact**

Nick Howe

GRACosway

[nhowe@gracosway.com.au](mailto:nhowe@gracosway.com.au)

M: +61 407 183 221

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>

For personal use only